Send to

Choose Destination
Int Neurourol J. 2011 Jun;15(2):61-3. doi: 10.5213/inj.2011.15.2.61. Epub 2011 Jun 30.

Potential targeting of siglecs, mast cell inhibitory receptors, in interstitial cystitis.

Author information

Department of Pharmacology, Inha University School of Medicine, Incheon, Korea.


Mast cell increases and activation are detected in the chronic inflammatory bladder disease interstitial cystitis (IC), and their proinflammatory mediators are felt to contribute to regional pelvic pain and inflammatory pathophysiology. The immunoreceptor tyrosine-based inhibition motif-containing sialic acid-binding immunoglobulin-like lectins (Siglecs) expressed in mast cells could be evaluated as in vivo signaling regulators capable of inhibiting IC-related mast cell activation.


Interstitial cystitis; Mast cells; Sialic acid binding Ig-like lectin (Siglec); Urinary bladder

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center